Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings

Bone Marrow Transplantation volume 27, pages 1255–1262 (2001)Cite this article

Abstract

The therapeutic benefits of allogeneic stem cell transplantation in patients with hematologic disorders are limited by the significant morbidity and mortality of graft-versus-host disease (GVHD). Current agents for the prevention and treatment of GVHD have limited efficacy and often result in toxic side-effects. Mycophenolate mofetil (MMF) is a new immunosuppressant with a selective mechanism of action. When employed following solid organ transplantation, MMF reduces the incidence and severity of acute rejection episodes. By selectively targeting activated lymphocytes, the active metabolite of MMF, mycophenolic acid (MPA), appears to augment the actions of standard immunosuppressant agents without adding overlapping toxicities. Studies of combination regimens that include MMF report that this agent permits a dose reduction of cyclosporine, tacrolimus, or corticosteroid, without increasing the incidence of acute rejection in solid organ transplants. Reports on the efficacy of MMF following stem cell transplantation in animal studies were mixed. However, the use of a non-myeloablative conditioning regimen with a post-graft immunosuppressive regimen of MMF and cyclosporine was able to sustain stable mixed chimeras in 60% to 80% of dogs who received hematopoietic grafts from DLA-identical littermates. MMF has demonstrated activity in preliminary clinical trials for GVHD prophylaxis, and treatment of acute or chronic GVHD. Larger clinical trials are warranted to determine the optimum dose and route of MMF administration for GVHD, as well as the comparative safety and efficacy of MMF-containing regimens. Bone Marrow Transplantation (2001) 27, 1255–1262.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Article 13 April 2024

Arnon Nagler, Myriam Labopin, … Mohamad Mohty

References

  1. Anasetti C, Hansen JA . Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors Transfusion Sci 1994 15: 221–230

    Article  CAS  Google Scholar 

  2. Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from The Eastern Cooperative Oncology Group (ECOG) Bone Marrow Transplant 1997 19: 577–600

    Article  CAS  PubMed  Google Scholar 

  3. Deeg HJ . Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients Bone Marrow Transplant 1994 14: (Suppl. 4) S56–S60

    PubMed  Google Scholar 

  4. Diasio RB, LoBuglio AF . Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG, Limbird LE, Molinoff PB et al (eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th edn McGraw-Hill: New York 1996 pp 1291–1307

    Google Scholar 

  5. Eugui EM, Almquist SJ, Muller CD, Allison AC . Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion Scand J Immunol 1991 33: 161–173

    Article  CAS  PubMed  Google Scholar 

  6. Simmons WD, Rayhill SC, Sollinger HW . Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection Drug Safety 1997 17: 75–92

    Article  CAS  PubMed  Google Scholar 

  7. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW . Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients Transplantation 1996 62: 666–672

    Article  CAS  PubMed  Google Scholar 

  8. Grinyó JM . Mycophenolate-update after it has come of age Nephrol Dial Transplant 1999 14: 31–34

    Article  PubMed  Google Scholar 

  9. Bornhäuser M, Schuler U, Pörksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation Transplantation 1999 67: 499–504

    Article  PubMed  Google Scholar 

  10. Kiehl MG, Armstrong V, Basara N et al. Intravenous mycophenolate mofetil plus prednisolone and cyclosporine in the prophylaxis of GVHD after stem cell transplantation 41st Annual American Society of Hematology Meeting 1999 Abstr. 671

  11. Basara N, Blau WI, Kiehl MG et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient Transplant Proc 1998 30: 4087–4089

    Article  CAS  PubMed  Google Scholar 

  12. Mookerjee B, Altomonte V, Vogelsang G . Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus Bone Marrow Transplant 1999 24: 517–520

    Article  CAS  PubMed  Google Scholar 

  13. Halloran P, Mathew T, Tomlanovich S et al. Mycophenolate mofetil in renal allograft recipients Transplantation 1997 63: 39–47

    Article  CAS  PubMed  Google Scholar 

  14. Pirsch JD, Sollinger HW . Mycophenolate mofetil – clinical and experimental experience Ther Drug Monit 1996 18: 357–361

    Article  CAS  PubMed  Google Scholar 

  15. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 1998 66: 507–515

    Article  CAS  PubMed  Google Scholar 

  16. Jain AB, Hamad I, Rakela J et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients. An interim report Transplantation 1998 66: 1395–1398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sievers TM, Rossi SJ, Ghobrial RM et al. Mycophenolate mofetil Pharmacotherapy 1997 17: 1178–1197

    CAS  PubMed  Google Scholar 

  18. European Mycophenolate Mofetil Cooperative Study Group . Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 1995 345: 1321–1325

    Article  Google Scholar 

  19. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group . A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 1996 61: 1029–1037

    Article  Google Scholar 

  20. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group . Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 1995 60: 225–232

    Article  CAS  PubMed  Google Scholar 

  21. van Leeuwen L, Guiffre AK, Sewell WA et al. Administration of mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation Transplantation 1998 64: 1097–1101

    Article  Google Scholar 

  22. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 1997 89: 3048–3054

    CAS  PubMed  Google Scholar 

  23. Sandmaier BM, Yu C, Gooley T et al. Haploidentical stem cell allografts after nonmyeloablative therapy in a preclinical large animal model 41st Annual American Society of Hematology Meeting 1999 Abstr. 1424

  24. Yu C, Seidel K, Nash RA et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts Blood 1998 91: 2581–2587

    CAS  PubMed  Google Scholar 

  25. Renner U, Platzbecker U, Freiberg-Richter J et al. Intravenous mycophenolate mofetil (MMF) after allogeneic blood stem cell transplantation. Results of a dose-finding study 41st Annual American Society of Hematology Meeting 1999 Abstr. 681

  26. Basara N, Blau WI, Kiehl MG et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant recipients 40th Annual American Society of Hematology Meeting 1998 Abstr. 4419

  27. McSweeney P, Niederwieser D, Shizuru J et al. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF) 41st Annual American Society of Hematology Meeting 1999 Abstr. 1742

  28. Niederwieser D, Wolff D, Hegenbart U et al. Hematopoietic stem cell transplants (HSCT) from HLA-matched and 1-allele mismatched unrelated donors using a nonmyeloablative regimen 41st Annual American Society of Hematology Meeting 1999 Abstr. 2506

  29. Basara N, Blau WI, Römer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients Bone Marrow Transplant 1998 22: 61–65

    Article  CAS  PubMed  Google Scholar 

  30. Kiehl MG, Armstrong V, Basara N et al. Intravenous mycophenolate mofetil plus prednisolone and cyclosporine in the prophylaxis of GVHD after stem cell transplantation 41st Annual American Society of Hematology Meeting 1999 Abstr. 671

  31. Basara N, Blau IW, Kiehl MG et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in bone marrow transplant patients: three years' experience 41st Annual American Society of Hematology Meeting 1999 Abstr. 690

  32. Abhyankar S, Godder K, Christiansen N et al. Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil 40th Annual American Society of Hematology Meeting 1998 Abstr. 4467

    Google Scholar 

  33. Ilhan O, Celebi H, Arat M et al. Treatment of acute and chronic graft versus host disease with mycophenolate mofetil 41st Annual American Society of Hematology Meeting 1999 Abstr. 4873

  34. Pallotta-Filho RS, Barbosa JAL, Macedo MCMA et al. The use of mycophenolate mofetil in the treatment of refractory chronic graft versus host disease 40th Annual American Society of Hematology Meeting 1998; Abstr. 4489

    Google Scholar 

  35. Redei I, Langston AA, Cherry JK et al. Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GVHD 41st Annual American Society of Hematology Meeting 1999 Abstr. 698

  36. Roberts T, Koc Y, Sprague K et al. Mycophenolate mofetil (MMF) for the treatment of chronic graft versus host disease (cGVHD) of the liver 41st Annual American Society of Hematology Meeting 1999 Abstr. 697

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Johns Hopkins Oncology Center, Baltimore, MD, USA

    GB Vogelsang & S Arai

Authors
  1. GB Vogelsang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogelsang, G., Arai, S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27, 1255–1262 (2001). https://doi.org/10.1038/sj.bmt.1703076

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703076

Keywords

This article is cited by

Search

Advanced search

Quick links